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Abstract
An important standard for childhood immunization is simultaneous administration of all age-
eligible doses of vaccines. Vaccination coverage for ≥4 doses of pneumococcal conjugate vaccine 
(PCV) for children 19–35 months has not achieved the Healthy People 2020 objective of 90% in 
the United States, and the fourth dose of PCV is commonly missed in the series. Research has not 
been conducted on the factors associated with missed opportunities for simultaneous 
administration of the fourth dose of PCV. A missed opportunity for simultaneous administration of 
the fourth dose of PCV is characterized as failing to administer an age-appropriate fourth dose of 
PCV to children when in the same provider visit the children did receive other age-eligible 
vaccines. During the period of 2008–2015, 4.5% to 7.8% of young children in the United States 
experienced missed opportunities for simultaneous administration of the fourth dose of PCV; 
across all selected factors, the proportion of missed opportunities varied from 4.1% to 11.3%. The 
timeliness of the first through the third doses of PCV vaccination, and age group of mothers were 
factors significantly related to missed opportunities for simultaneous administration of the fourth 
dose of PCV; the adjusted prevalence ratios ranged from 1.2 to 2.0. Missed opportunities could be 
reduced by provider implementation of systems to ensure that all recommended vaccines are 
offered at each visit. Systems tools providers could use to reduce missed opportunities include 
patient recall, provider reminders, standing orders, extended office hours, and use of immunization 
information systems (IIS).
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INTRODUCTION
Simultaneous administration of all age-eligible vaccines recommended by the Advisory 
Committee on Immunization Practices (ACIP) is a powerful strategy for raising vaccination 
coverage, acquiring and sustaining the national objective of vaccination coverage levels for 
children 19–35 months in the United States (CDC, 2011; USDHHS 1992; King et al., 1994). 
Simultaneous administration of childhood vaccines is characterized as administering more 
than one vaccine at the same healthcare visit, at different anatomic sites, and not combined 
in the same syringe (CDC, 2011). One significant reason related to low vaccination coverage 
is the failure to simultaneously administer all age-eligible vaccines to children (King et al., 
1994; Luman et al., 2009).
Streptococcus pneumoniae is a leading cause of serious illness, including bacteremia, 
meningitis, and pneumonia among children and adults worldwide (Nuorti et al., 2010; 
Thigpen et al., 2011). Approximately 10% of all patients with invasive pneumococcal 
disease die of their illness (Pilishvili et al., 2012; Robinson et al., 2001). Following the 
introduction of the pneumococcal conjugate vaccines (PCV) in the United States, the overall 
invasive pneumococcal disease rate decreased from 100 cases per 100,000 people in 1998 to 
9 cases per 100,000 in 2015 (CDC, 2017). However, Streptococcus pneumoniae continues to 
cause a variety of common clinical syndromes, despite vaccination programs for children 
and some adults (Huang et al., 2011).
Invasive pneumococcal disease caused by serotypes included in currently available vaccines 
is preventable. In 2000, the ACIP recommended routine use of 7-valent pneumococcal 
conjugate vaccine (PCV7) for all infants and young children (CDC, 2008). In February 
2010, a new 13-valent pneumococcal conjugate vaccine (PCV13) was approved by the FDA 
and has since replaced PCV7 (CDC, 2010). The ACIP recommends that the 13-valent 
pneumococcal conjugate vaccine (PCV13) be used for all children aged <5 years (Mung et 
al., 2010). For routine immunization of infants, PCV13 is recommended as a 4-dose series at 
age 2, 4, 6, and 12–15 months (CDC, Feburary 2016). The fourth dose of PCV is critical in 
boosting antibody titers and optimizing population level protection (CDC, 2011). 
Vaccination coverage from the National Immunization Survey-Child (NIS-Child) indicated 
that the fourth dose of PCV is among the most commonly missed vaccines for children (NIS, 
2015). In 2015, an estimated 15.9% (approximately 1 million) of children aged 19–35 
months in the United States were at risk because they had not received their fourth dose of 
PCV (Hill et al., Vaccination coverage for ≥4 PCV for children 19–35 months has never 
gained the 90% objective of Healthy People 2020(Hill et al., 2016; USDHHS, 2017). To 
increase vaccination of children with the fourth dose of PCV, one of the immunization 
strategies for healthcare practices and providers is to reduce missed opportunities for 
simultaneous administration of the fourth dose of PCV vaccine (CDC, 2011; USDHHS 
1992; King et al., 1994). Risk factors for missed opportunities for simultaneous 
administration of the fourth dose of PCV have not been previously examined. This study 
analyzes 2008–2015 NIS-Child data, depicts the trend in missed opportunities, measures the 
prevalence of missed opportunities by selected factors, and determines significant risk 
factors for missed opportunities for simultaneous administration of the fourth dose of PCV.
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MATERIALS AND METHODS
Study population
Vaccination coverage for ≥4 PCV had been increasing from 2001 through 2007, and PCV 
coverage was relatively stable during 2008–2015. Therefore, NIS-Child data collected from 
2008 through 2015 were analyzed in this study. The NIS-Child is conducted by the National 
Center for Immunization and Respiratory Diseases (NCIRD), Centers for Disease Control 
and Prevention (CDC) to generate national, state, and selected local area estimates of 
immunization rates annually for children 19–35 months in the United States. The NIS-Child 
has two phases of data collection. First, independent surveys of households with cellular and 
landline telephones are conducted. During the telephone call, children’s sociodemographic 
characteristics are collected, and consent to contact children’s immunization providers is 
obtained. Second, mailed surveys are sent to children’s immunization providers to acquire 
the children’s immunization history. Specific explanation of the sample design, 
immunization history questionnaire, data preparation, quality control, and weighting process 
of the NIS-Child have been published elsewhere (CDC, September 2016).
Vaccination and socio-demographic factors
In agreement with ACIP recommendations, four doses of PCV should be administered to 
children during their first two years of life in the United States (CDC, Feburary 2016). In 
this study, if the first, second, and third dose of PCV are given to children by age 2, 4, and 6 
months (i.e. before reaching 3, 5, and 7 months), the children are defined as on-time for the 
first, second, and third doses of PCV, respectively. For the remaining children, those with 
missing values of age in months at vaccination are defined as late in receiving the first 
through the third dose of PCV. The fourth dose of PCV is recommended for children at age 
12–15 months.
For children who are administered the first 3 doses of PCV vaccines but the fourth dose of 
PCV vaccine is not administered, a missed opportunity for simultaneous administration of 
the fourth dose of PCV is defined as failing to administer an age-appropriate fourth dose of 
PCV to children, during the same provider visit where the children received other age-
eligible vaccines. The age eligible period is eight weeks or more after receipt of the 3rd dose 
of PCV. The fourth dose of PCV is only necessary for children who received the first three 
doses of PCV before age 12 months, or for children at high risk who received the first three 
doses at any age (CDC, Feburary 2016; Dietz et al., 1994).
This study included a group of sociodemographic factors which have been found to be 
correlated with child vaccination status (Luman et al., 2001; Luman et al., 2005; Zhao et al., 
2010). A total of 13 variables, including timeliness of child’s receipt of the first, second, and 
third dose of PCV, mother’s age group, education level and marital status, first born and 
health insurance status of the child, number of children in family, child’s race/ethnicity, 
family poverty level, and number and type of vaccination providers, were included in this 
study to examine the risk factors associated with missed opportunities for simultaneous 
administration of the fourth dose of PCV.Research protocols for the evaluation were 
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reviewed by the CDC’s National Center for Health Statistics (NCHS) Research Ethics 
Review Board (ERB).
Analysis methods
This study was analyzed NIS-Child data from 2008 through 2015 to estimate the trends in 
the percentage of children with missed opportunities for simultaneous administration of the 
fourth dose of PCV vaccine; the combined 2008–2015 data were used in prevalence analysis 
for the factors selected (Li et al., 2009). All of the data analyses in this study were 
performed with SUDAAN 11.0.0 (RTI, 2012). One way and two way weighted categorical 
data analysis were applied to trend and univariate factor analysis. Unadjusted prevalence 
ratios between categories for each factor was used to assess the association of that factor 
with missed opportunities. A multivariable logistic regression model (Hosmer et al., 2000) 
was implemented with all of the 13 variables to identify the statistically significant factors 
associated with missed opportunities in the model. The model adjusted prevalence ratios 
(APR) were calculated for each of all 13 factors to assess the association of each factor with 
missed opportunities, the final model retains all factors regardless of significance.
RESULTS
Trend in proportion of missed opportunities for simultaneous administration of the fourth 
dose of PCV in years 2008–2015.
The prevalence of children with at least one missed opportunity for simultaneous 
administration of the fourth dose of PCV for children 19–35 months in the United States 
from 2008–2015 varied between 4.5% and 7.8% (Figure 1), with median of 5.7% and mean 
of 5.9%. The number of children with missed opportunities for simultaneous administration 
of the fourth dose of PCV decreased from approximately 479,000 in 2008 to 256,000 in 
2015, with median of 331,000 and mean of 351,000. During this 8 years period, the 
prevalence of missed opportunities dropped significantly; the average decrease is about 0.4% 
per year and the linear trend is significant with P-value < 0.001.
Prevalence in missed opportunities for simultaneous administration of the fourth dose of 
PCV by vaccination and socio-demographic components using combined 2008–2015 
National Immunization Survey-Child data.
This study showed the weighted prevalence (%) and 95% confidence intervals (CI), and the 
unadjusted prevalence ratios with 95% CI in missed opportunities for simultaneous 
administration of the fourth dose of PCV by timeliness of the first three doses of PCV 
vaccination, and 10 other selected socio-demographic factors in Table 1. Overall of the 13 
factors considered, the prevalence of missed opportunities for the fourth dose of PCV ranged 
from 4.1% to 11.3%, with mean of 6.5% and median of 6.2%. The delay in administering 
the first, second, and third dose of PCV vaccine was associated with the largest missed 
opportunity prevalence of 10.1%, 11.3%, and 11.3%. Among the remaining 10 factors, non-
Hispanic black children had the next highest prevalence rate (7.5%) in missed opportunities. 
Prevalence of missed opportunities was 7.4% for children living in families below poverty 
level, or children receiving all vaccination from public providers. Children who received the 
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3rd dose of PCV on-time had the lowest percentage of missed opportunities (4.1%) for 
simultaneous administration of the 4th dose of PCV among all categories of all 13 factors.
Multivariable logistic regression analysis of the association between all factors and 
missed opportunities for simultaneous administration of the fourth dose of PCV with 
combined 2008–2015 National Immunization Survey-Child data.
All adjusted prevalence ratios (APR) of missed opportunities for simultaneous 
administration of the fourth dose of PCV were demonstrated in Table 2. The presence of 
underlying late vaccination of the first 3 doses of PCV were significantly correlated to the 
risk for missed opportunities, after controlling for all other factors. Children late in receiving 
the first, second, and third dose of PCV vaccination were 1.2, 1.4, and 2.0 times more likely 
(95% confidence interval [CI]: 1.02–1.34, 1.20–1.58, 1.77–2.23) to miss the opportunity for 
simultaneous administering the fourth dose of PCV compared with children with on-time in 
receiving the first 3 doses of PCV. Delay in receiving the third dose of PCV was related to 
the highest APR of missed opportunities among all of the 13 factors analyzed in this study. 
Mother’s age ≤ 29 years was positively associated with missed opportunities for the fourth 
dose of PCV, compared to mother’s age ≥ 30 years, (APR= 1.16; 95% CI= 1.06, 1.27). The 
remaining socio-demographic factors were not significantly associated with missed 
opportunities in the multivariable analyses.
DISCUSSIONS
This study showed that prevalence of missed opportunities for simultaneous administration 
of the fourth dose of PCV decreased significantly from 7.8% to 4.5% from 2008 to 2015. 
This current research determined that delays in receipt of the first, second, and third dose of 
PCV are the most significant risk factors related to missed opportunities for simultaneous 
administration of the fourth dose of PCV. To reduce missed opportunities for simultaneous 
administration of the fourth dose of PCV, immunization providers should be encouraged to 
adhere to the National Vaccine Program Office’s Standards for Pediatric Immunization 
Practice (USDHHS, 1992). Among the 17 recommended practices, three are most relevant to 
reduce missed opportunities: (1). Administering vaccines simultaneously (at the same visit), 
in accordance with recommendations from the ACIP, the American Academy of Pediatrics, 
and the American Academy of Family Physicians is safe, effective and indicated. Although 
the immunization schedule provides age flexibility for administering certain vaccine doses, 
simultaneous administration decreases the number of visits needed and the potential for 
missed doses and enables earlier protection. When indicated vaccines are not simultaneously 
administered, arrangements should be made for the patient’s earliest next return to receive 
the needed vaccination(s). (2). Healthcare professionals should review the vaccination status 
of all patients at all health care visits to minimize the number of missed opportunities to 
vaccinate. This review should determine whether the patient has received any vaccinations 
elsewhere or is at high risk for disease or undervaccination. This information should be 
documented in the patient’s chart and preventive health summary. (3). Healthcare 
professionals or others who administer vaccinations should be knowledgeable and receive 
continuing education in vaccine storage and handling; the recommended vaccine schedule, 
contraindications, and administration techniques; treatment and reporting of adverse events; 
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vaccine benefit and risk communication; and vaccination record maintenance and 
accessibility. CDC sponsors distance-based training opportunities (eg, satellite broadcasts, 
web-based training, videotapes, self-administered print materials) for healthcare 
professionals.
Timing of the third dose of PCV is important in finding age eligible missed opportunities for 
the fourth dose of PCV. The age eligible period is eight weeks or more after receipt of the 
3rd dose of PCV, however this interval requirement does not have significant impact on the 
missed opportunities since only 2.1% children in our analysis had less than an 8 week 
interval between their third dose of PCV and the visit where a missed opportunity to 
vaccinate was observed. For children who start late or fall behind on recommended 
vaccinations of PCV, ACIP’s recommended childhood immunization schedule also includes 
a catch-up schedule for PCV (CDC, February 2016).
Education of parents/guardians about the benefits and risks of vaccination in a culturally 
appropriate manner and in easy-to-understand language might be another possible strategy 
for reducing missed opportunities (USDHHS, 1992; Seeber et al., 2017; Awadh et al., 2014). 
Health care professionals should allow sufficient time with parents/guardians to discuss the 
benefits of vaccines, the diseases that they prevent, any known risks from vaccines, the 
immunization schedule and the need to receive vaccines at the recommended ages and to 
answer any questions parents may have
Use of systems to remind parents/guardians, patients, and healthcare professionals when 
vaccinations are due and to recall those who are overdue is an evidence-based strategy in 
reducing missed opportunities for simultaneous administration of the fourth dose of PCV. 
This is also one of the best practices in the Standards for Pediatric Immunization Practice. 
Patient reminder/recall interventions inform individuals that they are due (reminder) or 
overdue (recall) for specific vaccinations. Patient reminders/recalls can be mailed or 
communicated by telephone; an autodialer system can be used to expedite telephone 
reminders. Patients who might be at high risk for not complying with medical 
recommendations, for example, those who have missed previous appointments, should 
receive more intensive follow-up. Providers’ client reminder and recall system have been 
verified to be a critical strategy to catch every missed opportunity for simultaneous 
administration of the fourth dose of PCV, and this system must be continued (The Guide to 
Community Preventive Services, 2015). Similarly, provider reminder systems alert 
healthcare professionals when vaccines are due or overdue for their patients. Notices should 
be placed in paper or electronic patient charts or communicated to healthcare professionals 
by computer or other means. Immunization information systems (IIS) can facilitate 
automatic generation of reminder/recall notices.
The results of this study had several limitations. The NIS-Child RDD (Random Digital 
Dialed) sample may not represent the whole target population of 19–35 month children in 
the US. Some of the providers do not respond to the Immunization History Questionnaire, 
and measurement errors occur in reporting childhood vaccination status by parents/
providers. Even if a weighting technique has been adopted to control sampling and non-
sampling error, all of those factors could still cause certain bias in the estimation of missed 
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opportunities (Kirk et al., 2017). Further, missed opportunities for simultaneous 
administration of the fourth dose of PCV are counted for provider visit where a child 
received other age-eligible vaccines but not the fourth dose of PCV. However, there might be 
other opportunities such as children who visited a medical provider for reasons other than 
vaccination and did not receive any vaccines at that visit. Thus, this research could under-
estimate missed opportunities for simultaneous administration of the fourth dose of PCV 
(Nuorti et al., 2010; Luman et al., 2005). Also, this is an observational study with survey 
data, which can’t demonstrate a causal inference between factors and missed opportunities. 
Finally, this study evaluated the prevalence of missed opportunities for simultaneous 
administration of the fourth dose of PCV for the children who received the first three doses 
of PCV before 12 months of age. Since we don’t identify children at high risk in NIS, we 
may have excluded some high risk children with three doses, at least one received at or after 
12 months, who still should get the 4th dose of PCV.
CONCLUSION
Missed opportunities could be reduced by provider implementation of systems to ensure that 
all recommended vaccines are offered at each visit. Strategies providers could use to reduce 
missed opportunities for simultaneous administration of the fourth dose of PCV include 
patient recall, provider reminders, standing orders, extended office hours, and use of 
immunization information systems (IIS).
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Figure 1. 
Trend in proportion of missed opportunities for simultaneous administration of the fourth 
dose of PCVa for children 19–35 months in the United States, National Immunization 
Survey-Child, 2008–2015.
a
 Pneumococcal conjugate vaccine.
Zhao et al. Page 10
Int J Sci Res Methodol. Author manuscript; available in PMC 2020 February 10.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Zhao et al. Page 11
Table 1.
Prevalence in missed opportunities for simultaneous administration of the fourth dose of PCVa by vaccination 
and socio-demographic factors for children 19–35 months in the United States, using combined 2008–2015 
National Immunization Survey-Child data.
Factors Un-weighted sample size 
(weighted %)
Weighted prevalence in missed 
opportunities % (95% CIb)
Unadjusted 
prevalence ratios 
(95% CI) 
compared to 
reference level
Total 131464 5.9 (5.7, 6.2)
Timeliness of the First 
dose of PCV
Late 14451 (13.3) 10.1 (9.2, 11.1) 1.9(1.7,2.1)
On-timec 112648(86.7) 5.5 (5.2, 5.7)
Timeliness of the Second 
dose of PCV
Late 23680 (22.2) 11.3(10.5,12.0) 2.4 (2.2, 2.6)
On-timec 101622 (77.8) 4.8 (4.5, 5.0)
Timeliness of the Third 
dose of PCV
Late 33401 (31.2) 11.3(10.7,11.9) 2.7 (2.5, 3.0)
On-timec 89224 (68.8) 4.1(3.9,4.4)
Years of formal education 
of mothers
≤ 12 years 38186(46.8) 6.9 (6.5, 7.3) 1.4(1.3,1.5)
≥ 13 yearsc 93278 (53.2) 5.1 (4.8,5.3)
Number of children in 
household
ld 32458 (25.7) 5.2 (4.7, 5.6) 1.2(1.1,1.3)
≥2 99006 (74.3) 6.2(5.9,6.5)
Mother’s marital status Marriedc 96970 (65.6) 5.3 (5.0, 5.6) 1.4(1.2,1.5)
Not married 32945 (34.4) 7.2 (6.7, 7.7)
Mother’s age ≤ 29 years 45879 (42.6) 6.9 (6.5, 7.4) 1.3(1.2,1.5)
≥ 30 yearsc 85585 (57.4) 5.2 (4.9, 5.5)
Type of vaccination 
providers
Public 13968(12.3) 7.4 (6.5, 8.3) 1.3(1.1,1.4)
Privatec 76823 (59.0) 5.9(5.6,6.2)
Number of vaccination 
providers l
c 88647 (66.2) 5.8(5.5,6.1) 1.1 (1.0, 1.2)
≥2 42365 (33.8) 6.2 (5.8, 6.7)
First born child Not 77647 (57.8) 6.3 (6.0, 6.7) 1.2(1.1, 1.3)
Yesc 53817(42.2) 5.3 (5.0, 5.7)
Children health 
insurance status
No 20451 (19.5) 7.3 (6.7, 7.9) 1.3(1.2,1.4)
Yesc 111013(80.5) 5.6(5.3,5.9)
Race/ethnicity of child White, non-Hispanicc 79038 (48.6) 5.3(5.0, 5.6)
Black, non-Hispanic 12555(13.0) 7.5 (6.7, 8.3) 1.4(1.3,1.6)
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Factors Un-weighted sample size 
(weighted %)
Weighted prevalence in missed 
opportunities % (95% CIb)
Unadjusted 
prevalence ratios 
(95% CI) 
compared to 
reference level
Hispanic 24866 (27.4) 6.6 (6.0, 7.2) 1.2(1.1,1.4)
Family poverty status At or Abovec 96200(61.6) 5.1(4.8,5.4) 1.5(1.3, 1.6)
Below 30774 (32.9) 7.4 (6.9, 7.9)
a
Pneumococcal conjugate vaccine.
bConfidence Interval.
c
Reference Level.
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Table 2.
Adjusted prevalence ratios (APR) of missed opportunities for simultaneous administration of the fourth 
dose of PCVaby timeliness of the first three doses of PCV vaccination and selected socio-demographic 
factors for children 19–35 months in the United States with combined 2008–2015 National 
Immunization Survey-Child data.
Factors Comparison Adjusted Prevalence Ratios (APR)
Ratio (95%CIb)
Timeliness of the First dose of PCV Late vs. On-time 1.17(1.02,1.34)
Timeliness of the Second dose of PCV Late vs. On-time 1.38(1.20, 1.58)
Timeliness of the Third dose of PCV Late vs. On-time 1.99(1.77,2.23)
Mother’s age ≤ 29 vs. ≥ 30 1.16(1.06,1.27)
Firstborn child Not vs. Yes 1.11(0.98,1.25)
Children health insurance status No vs. Yes 1.10(0.99,1.21)
Years of formal education of mothers ≤ 12 vs. ≥ 13 1.08(0.98 1.19)
Number of children in household ≥ 2 vs. 1 1.01 (0.89, 1.16)
Mother’s marital status Not married vs. Married 1.03 (0.93, 1.15)
Type of vaccination providers Public vs. Private 0.99(0.86, 1.14)
Number of vaccination providers ≥ 2 vs. 1 1.07(0.98, 1.18)
Family poverty status Below vs. At/Above 1.08(0.97,1.20)
Race/ethnicity of child Black vs. White, non-Hispanic 1.14(1.00,1.29)
Hispanic vs. White, non-Hispanic 1.06(0.95,1.19)
a
Pneumococcal conjugate vaccine.
bConfidence Interval.
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